Related Experiment Video

Updated: May 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Novel oral anticoagulants in non-valvular atrial fibrillation

Tatjana S Potpara1, Gregory Y H Lip

  • 1Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.

Best Practice & Research. Clinical Haematology
|August 20, 2013
PubMed

Insights

Atrial fibrillation (AF) patients benefit from oral anticoagulation for stroke prevention. Novel oral anticoagulants (NOACs) offer improved safety and convenience over vitamin K antagonists (VKAs).

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Atrial fibrillation (AF) significantly increases stroke and thromboembolism risk.
  • Oral anticoagulation is the primary stroke prevention therapy for AF.
  • Risk assessment for stroke and bleeding is crucial for treatment decisions.

Purpose of the Study:

  • To review clinical trials of novel oral anticoagulants (NOACs) for stroke prevention in AF.
  • To discuss current thromboprophylaxis principles in AF based on risk profiles.
  • To cover practical aspects of NOAC therapy.

Main Methods:

  • Review of Phase III clinical trials for NOACs (dabigatran, rivaroxaban, apixaban).
  • Analysis of stroke and bleeding risk assessment tools.
  • Discussion of contemporary thromboprophylaxis strategies.

Main Results:

  • NOACs are at least as effective and safer regarding bleeding than vitamin K antagonists (VKAs).
  • Most AF patients with stroke risk factors gain net clinical benefit from anticoagulation.
  • NOACs offer greater convenience compared to VKAs.

Conclusions:

  • NOACs represent a significant advancement in AF stroke prevention.
  • Improved risk assessment and NOAC availability should enhance thromboprophylaxis rates.
  • This review provides guidance on NOAC use in diverse AF patient populations.

Keywords:
apixabanatrial fibrillationbleeding risk assessmentdabigatrannet clinical benefitnovel oral anticoagulantsoral anticoagulant therapyrivaroxabanstrokestroke preventionstroke risk assessmentvitamin K antagonistswarfarin

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...